Precipio Inc. reports impressive revenue growth of 30% in Q2-2024, with positive outlook moving forward.

From GlobeNewswire: 2024-07-17 09:00:00

Precipio, Inc., a specialty cancer diagnostics company, reported unaudited revenue growth from $3.4M in Q1-2024 to $4.4M in Q2-2024, a 30% increase in one quarter. The Pathology Division reached its breakeven point in June, with expectations of exceeding $1.5 million in monthly revenues by year end.

The Products Division has three key accounts rolling out a full portfolio of HemeScreen assays, with two expected to go live in Q3-2024 and the third in Q4-2024. Once onboarded, these accounts aim to surpass the division’s breakeven threshold, contributing significantly to revenue.

CEO Ilan Danieli expressed confidence in Precipio’s progress towards profitability. The company has withstood setbacks with determination and resilience. Increasing demand for offerings in both the pathology and products divisions indicates positive growth outlook for the second half of the year.



Read more at GlobeNewswire:: Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a